Although many clinicians believe that caffeine can induce or exacerbate the frequency of arrhythmias and ventricular premature beats (VPBs), the evidence for this view is anecdotal and tenuous. Caffeine, like theophylline, is a methylated xanthine. It has pharmacological actions as an adenosine receptor antagonist, and to a minor extent, a phosphodiesterase inhibitor.' It also induces catecholamine release, leading to a rise in blood pressure and reflex bradycardia. However, these humoral effects are only seen Subjects were asked to follow a 6 week protocol (fig 1) . On day 6 of each week an ambulatory electrocardiogram was applied at about 1700 hours and removed after 24 hours when venesection and an assessment of palpitations was undertaken. For the first two baseline weeks, each subject continued their normal diet and coffee intake. During weeks 3 and 4, jars of instant coffee (freeze dried and granulated), which contained either caffeinated or decaffeinated coffee, were provided weekly in a randomised double blind fashion. Each subject continued on their normal diet and received one jar of caffeinated and one jar of decaffeinated coffee over the two weeks. Subjects were instructed to consume at least three cups of coffee per day and the jars were weighed at the beginning and after completion of the study week. For weeks 5 and 6 the subjects adhered to a caffeine free diet, having been given-both verbal and written instruction on caffeine-containing food products and pharmaceuticals. Jars of coffee were again provided at weekly intervals in an identical manner.
DATA ANALYSIS
The VPB count was corrected to give an average count over 24 hours. Because of positive skew in the distribution of VPB counts and to achieve an approximately normal distribution, logarithmic transformation of counts was used in the subsequent analysis and discussion. The first two baseline VPB counts were used to determine repeatability as described previously. 14 Data were analysed using Excel v5-0 (Microsoft). Where appropriate, correlation coefficients and two factor analysis of variance were determined for coffee consumption, serum caffeine concentrations, palpitation scores, and 24 hour VPB counts.
Statistical significance was taken at the 5% level and power calculations were determined for 90% probability. Where appropriate, results are expressed as the mean with standard errors of the mean in parentheses.
Results
Thirteen subjects were recruited into the study and their baseline characteristics are detailed in table 2.
CAFFEINE EXPOSURE
The mean weekly consumption of coffee was 50.1 (2 6) g. There was a significant correlation between coffee consumption and serum caffeine concentrations during the caffeinated coffee weeks (r = 0 70; P < 0-001). During the four intervention weeks, significant changes in serum caffeine concentrations were achieved (P < 0-001; fig 2) . Two subjects had detectable caffeine concentrations during the caffeine-free diet/decaffeinated coffee week.
POWER AND REPEATABILITY OF BASELINE VPB COUNTS
The mean of the two baseline VPB counts was 2'63 (033). Excluding one outlier,'4 the mean of the differences between the baseline counts was 0-00096 with a coefficient of repeatability of 1-0. This gives a 90% power of detecting a difference of 0-46 from the baseline mean of the VPB counts. VPB baseline mean (fig 2) , or palpitation There were no significant correlations b serum caffeine concentrations and th counts (r = 0-04; P = 0 76) or palr scores (r = 007; P = 0-54). Howev4 palpitation scores showed a significant c tion with the VPB counts (r = 0Q34 0-003).
Discussion
We believe that this is the first randc double blind trial which has assessed t cacy of caffeine restriction in subjeci symptomatic palpitations secondary t pathic VPBs. 
